FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891944790> ?p ?o ?g. }

• W2891944790 endingPage "1551" @default.
• W2891944790 startingPage "1541" @default.
• W2891944790 abstract "Background The clinical effect of a drug-eluting stent in the femoropopliteal segment has not been investigated in a randomised trial with a contemporary comparator. The IMPERIAL study sought to compare the safety and efficacy of the polymer-coated, paclitaxel-eluting Eluvia stent with the polymer-free, paclitaxel-coated Zilver PTX stent for treatment of femoropopliteal artery segment lesions. Methods In this randomised, single-blind, non-inferiority study, patients with symptomatic lower-limb ischaemia manifesting as claudication (Rutherford category 2, 3, or 4) with atherosclerotic lesions in the native superficial femoral artery or proximal popliteal artery were enrolled at 65 centres in Austria, Belgium, Canada, Germany, Japan, New Zealand, and the USA. Patients were randomly assigned (2:1) with a site-specific, web-based randomisation schedule to receive treatment with Eluvia or Zilver PTX. All patients, site personnel, and investigators were masked to treatment assignment until all patients had completed 12 months of follow-up. The primary efficacy endpoint was primary patency (defined as a peak systolic velocity ratio ≤2·4, without clinically driven target lesion revascularisation or bypass of the target lesion) and the primary safety endpoint was major adverse events (ie, all causes of death through 1 month, major amputation of target limb through 12 months, and target lesion revascularisation through 12 months). We set a non-inferiority margin of −10% at 12 months. Primary non-inferiority analyses were done when the minimum sample size required for adequate statistical power had completed 12 months of follow-up. The primary safety non-inferiority analysis included all patients who had completed 12 months of follow-up or had a major adverse event through 12 months. This trial is registered with ClinicalTrials.gov, number NCT02574481. Findings Between Dec 2, 2015, and Feb 15, 2017, 465 patients were randomly assigned to Eluvia (n=309) or to Zilver PTX (n=156). Non-inferiority was shown for both efficacy and safety endpoints at 12 months: primary patency was 86·8% (231/266) in the Eluvia group and 81·5% (106/130) in the Zilver PTX group (difference 5·3% [one-sided lower bound of 95% CI −0·66]; p<0·0001). 259 (94·9%) of 273 patients in the Eluvia group and 121 (91·0%) of 133 patients in the Zilver PTX group had not had a major adverse event at 12 months (difference 3·9% [one-sided lower bound of 95% CI −0·46]; p<0.0001). No deaths were reported in either group. One patient in the Eluvia group had a major amputation and 13 patients in each group required target lesion revascularisation. Interpretation The Eluvia stent was non-inferior to the Zilver PTX stent in terms of primary patency and major adverse events at 12 months after treatment of patients for femoropopliteal peripheral artery disease. Funding Boston Scientific. The clinical effect of a drug-eluting stent in the femoropopliteal segment has not been investigated in a randomised trial with a contemporary comparator. The IMPERIAL study sought to compare the safety and efficacy of the polymer-coated, paclitaxel-eluting Eluvia stent with the polymer-free, paclitaxel-coated Zilver PTX stent for treatment of femoropopliteal artery segment lesions. In this randomised, single-blind, non-inferiority study, patients with symptomatic lower-limb ischaemia manifesting as claudication (Rutherford category 2, 3, or 4) with atherosclerotic lesions in the native superficial femoral artery or proximal popliteal artery were enrolled at 65 centres in Austria, Belgium, Canada, Germany, Japan, New Zealand, and the USA. Patients were randomly assigned (2:1) with a site-specific, web-based randomisation schedule to receive treatment with Eluvia or Zilver PTX. All patients, site personnel, and investigators were masked to treatment assignment until all patients had completed 12 months of follow-up. The primary efficacy endpoint was primary patency (defined as a peak systolic velocity ratio ≤2·4, without clinically driven target lesion revascularisation or bypass of the target lesion) and the primary safety endpoint was major adverse events (ie, all causes of death through 1 month, major amputation of target limb through 12 months, and target lesion revascularisation through 12 months). We set a non-inferiority margin of −10% at 12 months. Primary non-inferiority analyses were done when the minimum sample size required for adequate statistical power had completed 12 months of follow-up. The primary safety non-inferiority analysis included all patients who had completed 12 months of follow-up or had a major adverse event through 12 months. This trial is registered with ClinicalTrials.gov, number NCT02574481. Between Dec 2, 2015, and Feb 15, 2017, 465 patients were randomly assigned to Eluvia (n=309) or to Zilver PTX (n=156). Non-inferiority was shown for both efficacy and safety endpoints at 12 months: primary patency was 86·8% (231/266) in the Eluvia group and 81·5% (106/130) in the Zilver PTX group (difference 5·3% [one-sided lower bound of 95% CI −0·66]; p<0·0001). 259 (94·9%) of 273 patients in the Eluvia group and 121 (91·0%) of 133 patients in the Zilver PTX group had not had a major adverse event at 12 months (difference 3·9% [one-sided lower bound of 95% CI −0·46]; p<0.0001). No deaths were reported in either group. One patient in the Eluvia group had a major amputation and 13 patients in each group required target lesion revascularisation. The Eluvia stent was non-inferior to the Zilver PTX stent in terms of primary patency and major adverse events at 12 months after treatment of patients for femoropopliteal peripheral artery disease." @default.
• W2891944790 created "2018-09-27" @default.
• W2891944790 creator A5001070816 @default.
• W2891944790 creator A5002830709 @default.
• W2891944790 creator A5004851955 @default.
• W2891944790 creator A5006055514 @default.
• W2891944790 creator A5006083917 @default.
• W2891944790 creator A5011740789 @default.
• W2891944790 creator A5012299613 @default.
• W2891944790 creator A5015121795 @default.
• W2891944790 creator A5015790637 @default.
• W2891944790 creator A5016016981 @default.
• W2891944790 creator A5016620644 @default.
• W2891944790 creator A5016659006 @default.
• W2891944790 creator A5017066822 @default.
• W2891944790 creator A5018009312 @default.
• W2891944790 creator A5018121001 @default.
• W2891944790 creator A5020081204 @default.
• W2891944790 creator A5020986631 @default.
• W2891944790 creator A5024915551 @default.
• W2891944790 creator A5025956617 @default.
• W2891944790 creator A5026623030 @default.
• W2891944790 creator A5026681829 @default.
• W2891944790 creator A5029713831 @default.
• W2891944790 creator A5029900766 @default.
• W2891944790 creator A5030466081 @default.
• W2891944790 creator A5033103311 @default.
• W2891944790 creator A5033106782 @default.
• W2891944790 creator A5036329954 @default.
• W2891944790 creator A5036945349 @default.
• W2891944790 creator A5037212809 @default.
• W2891944790 creator A5037985285 @default.
• W2891944790 creator A5038012814 @default.
• W2891944790 creator A5038260027 @default.
• W2891944790 creator A5041902090 @default.
• W2891944790 creator A5045922184 @default.
• W2891944790 creator A5047386357 @default.
• W2891944790 creator A5048450300 @default.
• W2891944790 creator A5049820582 @default.
• W2891944790 creator A5052154025 @default.
• W2891944790 creator A5055482430 @default.
• W2891944790 creator A5057088455 @default.
• W2891944790 creator A5057759062 @default.
• W2891944790 creator A5057778311 @default.
• W2891944790 creator A5057955923 @default.
• W2891944790 creator A5058395932 @default.
• W2891944790 creator A5059674938 @default.
• W2891944790 creator A5059960901 @default.
• W2891944790 creator A5060942244 @default.
• W2891944790 creator A5061622833 @default.
• W2891944790 creator A5062406962 @default.
• W2891944790 creator A5065800281 @default.
• W2891944790 creator A5065918054 @default.
• W2891944790 creator A5065985671 @default.
• W2891944790 creator A5067172865 @default.
• W2891944790 creator A5067459586 @default.
• W2891944790 creator A5069567129 @default.
• W2891944790 creator A5072643638 @default.
• W2891944790 creator A5073076864 @default.
• W2891944790 creator A5073222315 @default.
• W2891944790 creator A5078615243 @default.
• W2891944790 creator A5082317115 @default.
• W2891944790 creator A5083180060 @default.
• W2891944790 creator A5083598377 @default.
• W2891944790 creator A5083909742 @default.
• W2891944790 creator A5084541567 @default.
• W2891944790 creator A5086494049 @default.
• W2891944790 creator A5086737942 @default.
• W2891944790 creator A5086939418 @default.
• W2891944790 creator A5087164834 @default.
• W2891944790 creator A5088314923 @default.
• W2891944790 creator A5089617485 @default.
• W2891944790 date "2018-10-01" @default.
• W2891944790 modified "2023-10-09" @default.
• W2891944790 title "A polymer-coated, paclitaxel-eluting stent (Eluvia) versus a polymer-free, paclitaxel-coated stent (Zilver PTX) for endovascular femoropopliteal intervention (IMPERIAL): a randomised, non-inferiority trial" @default.
• W2891944790 cites W1482348910 @default.
• W2891944790 cites W188696429 @default.
• W2891944790 cites W1977671695 @default.
• W2891944790 cites W1990802090 @default.
• W2891944790 cites W1998483781 @default.
• W2891944790 cites W2019734515 @default.
• W2891944790 cites W2029653225 @default.
• W2891944790 cites W2043517681 @default.
• W2891944790 cites W2101195219 @default.
• W2891944790 cites W2102187172 @default.
• W2891944790 cites W2118501388 @default.
• W2891944790 cites W2144985796 @default.
• W2891944790 cites W2148374679 @default.
• W2891944790 cites W2157205446 @default.
• W2891944790 cites W2168393911 @default.
• W2891944790 cites W2295508527 @default.
• W2891944790 cites W2407388140 @default.
• W2891944790 cites W2625747098 @default.
• W2891944790 cites W2739447339 @default.
• W2891944790 cites W2741019994 @default.
• W2891944790 cites W2772224170 @default.
• W2891944790 cites W2802747665 @default.
• W2891944790 cites W2803314168 @default.

• next